Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Should we be stopping new starts of patients who can be triaged for 2-3 months like prostate cancers on ADT when significant community spread of COVID-19 is detectable in our area?

8
9 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

I would for those patients requiring ADT, which is the way I interpreted the question. I want to elaborate more because @Dr. First Last brought up other scenarios we should consider and he brings some more good points: Many patients could get active surveillance for a period of time before ADT is co...

How would you approach a patient with a recent MI s/p DES who is being considered for neoadjuvant chemotherapy for TNBC?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Inova Schar Cancer Institute

This is mostly opinion as there is not data specific to this situation. First, I would coordinate closely with the cardiologist, preferably someone with knowledge of cardio-oncology. Presumably the patient is already on cardioprotective medications, such as beta blocker and ACE inhibitor, but if not...

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?

3
4 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University Medical Center

Among women with early-stage breast cancer and moderate penetrance breast cancer susceptibility genes, such as CHEK2, decisions about breast surgery are largely based upon personal preferences. According to data from large population-based studies, women with CHEK2 pathogenic variants have about a 2...

How long do you continue trastuzumab and pertuzumab after lumpectomy if you included both in a neoadjuvant regimen such as TCH-P?

4
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Private Practice and Digital Health

A total of one year for trastuzumab, including the part with chemotherapy, adjuvant or neoadjuvant. The benefit from addition of pertuzumab, as might have been predicted, was very small, since it is very hard to add any sizable benefit to trastuzumab without some logical risk stratification; for ER ...

How do you choose 1st line therapy for recurrent cervical cancer?

2
1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · University of California Irvine Medical Center

I use the Moore criteria and if the score is greater than or equal to 2, I will evaluate the patient for contraindications to bevacizumab and if none, I will counsel her to receive bevacizumab plus chemotherapy. The chemotherapy backbone is cisplatin-paclitaxel if the patient did not receive cisplat...

Which patients would you treat with relugolix instead of injectable GnRH agonist therapy?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Medical College of Wisconsin

I would consider relugolix for patients with: 1. Intermediate-risk prostate cancer that needs a short course of androgen deprivation therapy 2. Patients with biochemical relapse that would benefit from a short course of ADT and salvage RT2.5 Patient with pre-existing cardiac comorbidities 3. Potenti...

Do you offer IV iron first line to women with iron deficiency anemia from heavy menstrual bleeding?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

I offer first-line IV iron because oral iron cannot keep up with the losses from heavy menstrual bleeding, and the majority can't tolerate it. I routinely give a gram of LMW iron dextran in one hour, Feraheme (not ferumoxytol generic) 1,020 mg in 30 minutes, or ferric derisomaltose 1 gram in 30 minu...

Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?

1
2 Answers

Mednet Member
Mednet Member
Hematology · Oregon Health & Science University

The short answer is yes, there is a benefit to treating iron overload in a patient with hereditary hemochromatosis (HH) with cirrhosis. HH involves at least five mutations, most commonly in the HFE gene (common variants include C282Y and H63D), leading to hyperabsorption of iron and progressive accu...

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...